Semaglutide Market Faces Slump as Excess Stock Hits ₹100 Crore

The explosive growth in India's obesity therapy market has hit a significant roadblock as semaglutide sales decelerated sharply in May. After a massive surge driven by generic launches, the industry is now grappling with a massive inventory overhang that threatens to squeeze margins for distributors and manufacturers alike.

The Post-Patent Surge and Sudden Slowdown

The semaglutide market, currently valued at approximately ₹2,000 crore, experienced a massive boom in April following the drug going off-patent on March 20. This patent expiry triggered a flood of cheaper generic alternatives from major Indian pharmaceutical giants, including Sun Pharma, Dr. Reddy's, and Torrent Pharmaceuticals. In April, the market saw a staggering 50% month-on-month (m-o-m) growth in value and an 88% surge in volumes.

However, this momentum failed to carry into May. According to data from market research firm Pharmarack, the market growth slowed down significantly, with value growth dropping to just 6% m-o-m and unit growth cooling to 12%. This sudden deceleration has left the trade channel struggling to move the vast quantities of medicine dispatched during the April rush.

Inventory Overhang and Distribution Bottlenecks

The primary concern for industry stakeholders is the massive buildup of unsold stock. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), noted that stockists and wholesalers are currently holding 50–60 days of GLP-1 (semaglutide) inventory. This is significantly higher than the standard industry benchmark of 30–45 days.

Estimates suggest that the value of this excess stock sitting in the trade channel is close to ₹100 crore. Consequently, many channel partners have halted fresh procurement from pharmaceutical companies, opting to liquidate existing inventory before placing new orders. This pause in the supply chain could lead to a period of stagnation for manufacturers looking to capitalize on the obesity therapy trend.

Regulatory Impact and Competitive Landscape

Industry experts suggest that the moderation in sales might not just be a matter of supply and demand, but also a result of tightened regulatory oversight. Recent government advisories and prescribing restrictions stipulate that GLP-1 therapies must be prescribed only by qualified specialists. These guidelines, announced in April, may have acted as a cooling mechanism on the rapid, widespread prescribing seen during the initial hype.

Despite the semaglutide slowdown, the broader pharma landscape remains resilient. Eli Lilly’s Mounjaro (tirzepatide), another GLP-1 receptor agonist used for diabetes and obesity, remains the market leader. Mounjaro saw its sales rise by 12% to ₹136 crore in May. Overall, the ₹2.5 lakh crore organized pharma retail market grew by nearly 11%, largely supported by chronic disease therapies.

Key Takeaways

  • Massive Inventory Glut: The semaglutide trade channel is holding approximately ₹100 crore in excess stock, with wholesalers maintaining 50–60 days of inventory.
  • Growth Deceleration: After a 50% value surge in April, semaglutide market growth plummeted to just 6% in May.
  • Regulatory Hurdles: New government guidelines requiring specialist prescriptions for GLP-1 therapies are believed to be a contributing factor to the sales slowdown.